CORRECTION FROM SOURCE: Theranexus and BBDF Win FDA Approval

This press release updates an earlier issuance with updated language throughout.Phase III's primary endpoint will be visual acuity, with secondary endpoints including assessment of cognitive and motor

Related Keywords

United States , France , Paris , France General , French , Martin Pierre Laurent , Mathieu Charv , Marie Sebille , Craig Benson , Florence Portejoie , Thierry Lambert , Atomic Energy Commission , Batten Disease Foundation , Twitter , National Organization For Rare Disorders , Division Of Rare Diseases , Drug Administration , Beyond Batten Disease Foundation , Rare Diseases , Medical Genetics , Theranexu Chief Medical Officer Marie , Verbal Comprehension Index , Wechsler Intelligence Scale , Unified Batten Disease Rating Scale , French Alternative Energies , Euronext Growth , Rare Disorders , Gefallene Big Techs , Correction , Rom , Source , Theranexus , Bbdf , Approval , Efficacy , Endpoints , Hase , Trial , Valuate , Thatten , Ln3 , Disease ,